Pharmacotherapy is a second level of treatment that must be used in combination with lifestyle behavioral change. It is considered for individuals who have a body mass index (BMI) of >30 kg/m 2 and no contraindications to the medication or a BMI of >27 kg/m 2 with significant comorbidities. Compared with placebo, weight loss drugs have achieved at least a 5% weight loss at 52 weeks (Khera et al., 2016) . However, the undesirable side effects of weight loss medications are not uncommon, and individuals need to engage in sustained lifestyle change to maintain the weight loss.
An alternative approach that can lead to substantial weight loss and sustained weight loss is bariatric surgery (Ricci et al., 2015) . Criteria for eligibility for surgical treatment is (a) Class 3 obesity (BMI ≥ 40 kg/m 2 ), (b) Class 2 obesity (BMI = 35-39.9 kg/m 2 ) with at least two obesity-related comorbidities, or (c) failure to achieve a sustained weight loss with prior weight loss efforts (American Society for Metabolic and Bariatric Surgery, 2016). Maintenance of weight loss is a challenge post-surgery. Weight regain has been reported as early as 6 months postoperatively (Courcoulas et al., 2013) , and approximately one third of patients return to their preoperative weight within 10 years.
Each of the 10 articles included in this issue addresses distinct issues and challenges that we face in the treatment of children, adolescents, and adults with obesity. Five of the articles included in this issue focus on children or adolescents. Hand, Robinson, Stewart, Zhang, and Hand (2017) address weight stigma among adolescents. Two articles focus on children with special needs, an often overlooked group at increased risk for this chronic disease. Bennett, Kolko, Chia, Elliott, and Kalarchian (2017) review studies that evaulated treatment strategies for youth with intellectual and developmental disabilities. The second study (Polfuss, Simpson, Greenley, Zhang, & Sawin, 2017) focuses on parents of children who were diagnosed with autism, spina befida, or Down's Syndrome. Small, Thacker, Aldrich, Bonds-McClain, and Melnyk (2017) report on a pilot study with parent-child dyads among children ages 4 to 8 years who were overweight or obese. The fifth article (Choo, Kim, & Park, 2017) targeting childen uses geographc information systems to examine the neighborhood and its associations with health behaviors and obesity status.
The remaining five articles in this issue address obesity among adults from an array of perspectives. Greathouse, Faucher, and Hastings-Tolsma (2017) explore the new paradigm of a proposed link between the microbial composition in the gastrointestinal tract and obesity. Goode, Styn, Mendez, and Gary-Webb (2017) conduct a narrative review of randomized clinical trials that used SBT for weight loss to determine the rates of inclusion and reporting of results for African Americans. Given that African Americans have the highest prevalence of obesity, it is important to examine what strategies are effective for this group. Transitioning patients with severe obesity from the hospital to a nursing home has its challenges, which is addressed by Bradway, Felix, Whitfield, and Li (2017) . Petit Francis, Spaulding, Turkson-Ocran, and Allen (2017) conduct a systematic review to determine whether nurse-delivered weight management interventions improve weight outcomes, which is a unique perspective because weight loss studies are most commonly conducted by behavioral scientists. The article by Sereika, Zheng, Hu, Jiang, and Burke (2017) presents a novel statistical methodology to identify distinct latent classes of individuals in a weight loss trial who follow a single trajectory of behavior, for example, self-monitoring, as a function of age or time.
We are grateful to the contributing authors for the breadth that they provided for this issue and for raising the readers' awareness of the challenges that we as a discipline need to address for our patients and study participants with obesity. Looking to the future, we need to conduct more high-quality and theory-based randomized controlled trials testing interventions that address the needs of more diverse samples. Beyond improved methods, more mechanistic research is needed to examine the physiological and genetic pathways that lead to the development of obesity. Finally, our discipline needs to engage in translating interventions with proven efficacy into primary care settings and the community to have an impact on this major public health problem. 
